| This week's sponsor is Ajinomoto Bio-Pharma Services. | | | |
Today's Rundown Former Gilead CSO McHutchison takes charge at Assembly Biosciences Bayer to pay $240M to buy BlueRock cell therapy joint venture U.K. commits £250M to AI lab, seeks industry partners ORIC Pharma bags $55M to attack treatment resistance in cancer Apple, Eli Lilly and Evidation present first results from digital Alzheimer’s study Featured Story | | | Wednesday, August 7, 2019 Three weeks after Gilead announced his exit, John McHutchison, M.D., has landed at Assembly Biosciences—in the CEO seat. The nine-year Gilead veteran left his post of chief scientific officer and R&D chief on Friday. |
|
|
Top Stories Thursday, August 8, 2019 Bayer is set to pay $240 million (€214 million) upfront to buy the remaining stake in its cell therapy joint venture, BlueRock Therapeutics. The deal will give Bayer control of an induced pluripotent stem cell (iPSC) pipeline led by a late-preclinical Parkinson’s disease candidate. Thursday, August 8, 2019 The U.K. has unveiled plans to invest £250 million ($303 million) in a healthcare artificial intelligence lab in the belief it can help drive advances including the development of new dementia treatments. Thursday, August 8, 2019 ORIC Pharma raised $55 million in series D cash to push its pipeline of drugs aimed at quashing treatment-resistant cancers. The mezzanine round will fund its lead asset through phase 1b and into phase 2 and move a second program into the clinic. Thursday, August 8, 2019 Using iPhones and iPads, a study by Eli Lilly, Apple and Evidation explored digital biomarkers that could help spot people with early Alzheimer’s. Resources Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: BBK Worldwide The Study Voices survey challenges the myth that physicians won’t refer patients to clinical trials, and it identifies opportunities to engage physicians as partners in the enrollment process. Sponsored by: Cambrex The highest number of NCEs approved by the FDA…the fastest growing small molecule clinical pipeline reported in 20 years…these are exciting times for our industry. Sponsored by: Reprints Desk, Inc. Cut your research time in half - with an easy-to-use app for scientists that combines full-featured reference management with integrated search and on-demand document delivery. Sponsored by: XiltriX North America Find out in this article how your pharmaceutical organization can leverage IoT technologies and informatics integration to innovate and improve overall operational efficiencies. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. Latin America Healthcare Compliance Certificate Program September 23-26, 2019 4th FierceBiotech Drug Development Forum October 28-29, 2019 | Boston, MA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register NOW and start Pre-Boot Camp Preparation! | 